Funding for this research was provided by:
National Health and Medical Research Council (APP1079078)
Text and Data Mining valid from 2020-03-12
Received: 27 June 2019
Accepted: 26 February 2020
First Online: 12 March 2020
Ethics approval and consent to participate
: Ethical approval has been obtained from the University of Melbourne Human Research Ethics Committee (HREC No. 1750443). All participants will provide written informed consent.
: Not applicable.
: JP was Chair of the Medical advisory Board for Liraglutide 3 mg (Saxenda) for Novo Nordisk Australia and Has given lectures on the management of obesity for I Nova marketers of Duromine (Phentermine) and Contrave (Bupropion and Naltrexone).